Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9CUY
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,127
Award facts
- Contract value 100% obligated
- $19,127.12 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $19,127.12 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens (2 ml quantity) on January 8, 2026, with an ultimate completion date of January 9, 2026. This is a firm fixed-price, non-set-aside contract with performance at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen Drug Corp's parent company, Cencora, Inc. (doing business as AmerisourceBergen), which holds a significant Indefinite Delivery Contract with DLA Troop Support Medical valued at up to $999,999,999.00 through December 31, 2031. This IDC serves as the primary vehicle for delivering pharmaceutical products and medical supplies to support military healthcare programs globally.
Dupixent is a biologic immunosuppressant medication used to treat moderate-to-severe atopic dermatitis, asthma, and eosinophilic conditions. AmerisourceBergen's role as a prime pharmaceutical distributor under the DLA's Troop Support Medical program enables the company to supply critical brand-name and generic medications to Defense Health Agency facilities, military treatment centers, and other federal healthcare systems. The non-set-aside designation reflects full and open competition, demonstrating AmerisourceBergen's capability to compete effectively for federal pharmaceutical procurement requirements within the broader military healthcare supply chain.
Quick answers
Who was awarded contract SPE2DR26F9CUY?
SPE2DR26F9CUY was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 8, 2026.
How much is contract SPE2DR26F9CUY worth?
The government has obligated $19,127 on SPE2DR26F9CUY.
Is contract SPE2DR26F9CUY an order under another contract?
Yes. SPE2DR26F9CUY is a delivery order under SPE2DR25D1017, an indefinite delivery contract.
Was contract SPE2DR26F9CUY competed?
The extent of competition for SPE2DR26F9CUY was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award